Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133224 · ClinicalTrials.gov registry record · Phase 3
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
A Phase 3 study, sponsored by Cell Genesys.
- Terminated
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
NCT00133224: Clinical Trial Phase 3 study, sponsored by Cell Genesys.
NCT00133224 is a Phase 3 study that was terminated before completion, run by Cell Genesys. The registered enrollment target is 408 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00133224, a Phase 3 study, was terminated before completion, sponsored by Cell Genesys.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases with pain. Patients may have had up to one prior non-taxane chemotherapy treatment.
Interventions
- BIOLOGICAL Immunotherapy allogeneic GM-CSF secreting cellular vaccine
- DRUG Chemotherapy (docetaxel and prednisone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00133224
The ClinicalTrials.gov registry entry for NCT00133224 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cell Genesys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Immunotherapy allogeneic GM-CSF secreting cellular vaccine is the first listed.
NCT00133224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00133224 about?
NCT00133224 is a clinical study titled "Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients". The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone treatment in patients with prostate cancer who no longer respond to hormone the...
What is the current status of trial NCT00133224?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2005-07. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00133224?
The interventions under investigation include: Immunotherapy allogeneic GM-CSF secreting cellular vaccine (BIOLOGICAL), Chemotherapy (docetaxel and prednisone) (DRUG).
Who is sponsoring clinical trial NCT00133224?
This trial is sponsored by Cell Genesys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.